Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine

Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine

Abstract Background Prostatic acid phosphatase (PAP) is a prostate tumor antigen, and the target of the only FDA-approved anti-tumor vaccine, sipuleucel-T. We have previously reported in two clinical trials that a DNA vaccine encoding PAP (pTVG-HP) could elicit PAP-specific, Th1-biased T cells in pa...

Full description

Bibliographic Details
Main Authors: Ellen Wargowski, Laura E. Johnson, Jens C. Eickhoff, Lauren Delmastro, Mary Jane Staab, Glenn Liu, Douglas G. McNeel
Format: Article
Language:English
Published: BMJ Publishing Group 2018-03-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Sipuleucel-T
DNA vaccine
Prostate cancer
Prostatic acid phosphatase
Immune monitoring
Clinical trial
Online Access:http://link.springer.com/article/10.1186/s40425-018-0333-y

Internet

http://link.springer.com/article/10.1186/s40425-018-0333-y

Similar Items